Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,595.00
Bid: 1,594.50
Ask: 1,595.00
Change: -13.50 (-0.84%)
Spread: 0.50 (0.031%)
Open: 1,604.50
High: 1,609.00
Low: 1,586.50
Prev. Close: 1,608.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of GSK 2019 Form 20-F

9 Mar 2020 07:00

RNS Number : 3525F
GlaxoSmithKline PLC
09 March 2020
 

 

GlaxoSmithKline plcAnnual Report 2019 on Form 20-F

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that on 06 March 2020 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2019. GSK's 2019 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

Ordinary Shareholders may also elect to receive notification by email of the publication of financial reports by registering on www.shareview.co.uk.

A hard copy version of the GSK 2019 Annual Report, together with the Notice of Annual General Meeting will be available on or about 23 March 2020.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2020, free of charge, by either:

(i) writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on 0371 384 2991 (inside the UK) or +44 (0)121 415 7067 (outside the UK);

(ii) writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 800 990 1135 (US toll free) or +1 651 453 2128 (outside the US); or

(iii) contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

Victoria WhyteCompany Secretary06 March 2020

 

Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2019.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKKABDDBKBONK
Date   Source Headline
16th Jun 20237:00 amRNSExtension of FDA review period for momelotinib
12th Jun 20233:30 pmRNSDirector/PDMR Shareholding
7th Jun 20237:00 amRNSEU authorisation of GSK’s RSV vaccine Arexvy
6th Jun 20237:00 amRNSGSK receives US FDA file acceptance for Jemperli
1st Jun 20233:00 pmRNSTotal Voting Rights
22nd May 20233:30 pmRNSDirector/PDMR Shareholding
16th May 20232:00 pmRNSHolding(s) in Company
15th May 20233:30 pmRNSDirector/PDMR Shareholding
15th May 20233:00 pmRNSBlock listing Interim Review
12th May 20233:30 pmRNSDirector/PDMR Shareholding
12th May 20239:50 amRNSMenABCWY vaccine preliminary phase III results
12th May 20237:05 amRNSStatement: Zantac Litigation Update BC Canada
12th May 20237:00 amRNSGSK completes sale of shares in Haleon plc
11th May 20234:41 pmRNSGSK announces intention to sell shares in Haleon
9th May 20233:30 pmRNSDirector/PDMR Shareholding
4th May 20233:30 pmRNSDirector/PDMR Shareholding
3rd May 20236:20 pmRNSResult of AGM
3rd May 20236:00 pmRNSUS FDA approves GSK’s RSV vaccine for older adults
3rd May 20239:09 amRNSForm 8.3 - Allergy Therapeutics plc
2nd May 20233:00 pmRNSTotal Voting Rights
28th Apr 20235:01 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amRNSGSK RSV OA vaccine gains positive EMA CHMP opinion
26th Apr 20237:00 amRNS1st Quarter Results
25th Apr 20237:00 amRNSEMA validates Jemperli filing for new indication
20th Apr 20233:30 pmRNSDirector/PDMR Shareholding
19th Apr 20233:30 pmRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSGSK reaches agreement to acquire BELLUS Health Inc
17th Apr 20233:30 pmRNSDirector/PDMR Shareholding
17th Apr 20237:00 amRNSGepotidacin positive phase III data
3rd Apr 20233:00 pmRNSTotal Voting Rights
28th Mar 20237:00 amRNSPositive phase III RUBY results for Jemperli
27th Mar 20231:00 pmRNSPublication of 2023 AGM Notice
24th Mar 20239:59 amRNSStatement: Zantac (ranitidine) litigation
21st Mar 20233:30 pmRNSDirector/PDMR Shareholding
20th Mar 20233:30 pmRNSDirector/PDMR Shareholding
14th Mar 20237:05 amRNSPositive phase III results for MenABCWY vaccine
14th Mar 20237:00 amRNSNucala NDA accepted for review in China
13th Mar 20233:30 pmRNSDirector/PDMR Shareholding
10th Mar 20234:26 pmRNSGSK Annual Report 2022 on Form 20-F
10th Mar 202310:36 amRNSGSK publishes Annual Report 2022
2nd Mar 20237:00 amRNSFDA Ad Com votes to support GSK RSV OA vaccine
1st Mar 20233:00 pmRNSTotal Voting Rights
27th Feb 20233:30 pmRNSDirector/PDMR Shareholding
23rd Feb 20233:30 pmRNSDirector/PDMR Shareholding
23rd Feb 20237:00 amRNSViiV Healthcare announces Cabenuva positive data
22nd Feb 20233:30 pmRNSDirector/PDMR Shareholding
16th Feb 20237:00 amRNSNEJM publishes GSK RSV OA vaccine candidate trial
15th Feb 20234:04 pmRNSDirector/PDMR Shareholding
15th Feb 20234:00 pmRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.